Publications in collaboration with researchers from Hospital Universitario La Fe (22)

2024

  1. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651

2023

  1. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  2. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2749-2758

2022

  1. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  3. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

    European Thyroid Journal, Vol. 11, Núm. 5

2021

  1. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Leukemia and Lymphoma

  2. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  3. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Hematological Oncology, Vol. 37, Núm. 2, pp. 143-150

  4. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191

  2. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

    Cancer, Vol. 123, Núm. 19, pp. 3709-3716

2015

  1. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1005-1013

  2. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1014-1019

2014

  1. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

    Leukemia and Lymphoma, Vol. 55, Núm. 1, pp. 51-55

  2. High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma

    Leukemia and Lymphoma

  3. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica